Oxford Biomedica (LON:OXB) Now Covered by Jefferies Financial Group

Equities research analysts at Jefferies Financial Group began coverage on shares of Oxford Biomedica (LON:OXB) in a research note issued to investors on Monday,London Stock Exchange reports. The brokerage set a “buy” rating and a GBX 827 price target on the biopharmaceutical company’s stock. Jefferies Financial Group’s price target points to a potential upside of 36.47% from the stock’s previous close.

Several other analysts have also recently issued reports on the company. Stifel Nicolaus restated a “buy” rating and set a GBX 950 price objective on shares of Oxford Biomedica in a research note on Wednesday, March 11th. Deutsche Bank Aktiengesellschaft lifted their target price on Oxford Biomedica from GBX 735 to GBX 800 and gave the stock a “buy” rating in a research report on Friday, January 9th. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of GBX 687.

Oxford Biomedica Stock Down 1.5%

Shares of Oxford Biomedica stock traded down GBX 9.23 during trading on Monday, reaching GBX 606. The company had a trading volume of 1,195,569 shares, compared to its average volume of 629,297. The company has a debt-to-equity ratio of 322.11, a quick ratio of 1.67 and a current ratio of 1.89. Oxford Biomedica has a fifty-two week low of GBX 232.50 and a fifty-two week high of GBX 952. The firm’s fifty day moving average is GBX 755.89 and its 200-day moving average is GBX 665.45. The company has a market cap of £732.48 million, a price-to-earnings ratio of -16.73 and a beta of 1.04.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.